Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?
- 1 September 2000
- journal article
- research article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 53 (9) , 888-894
- https://doi.org/10.1016/s0895-4356(99)00214-0
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Assessing the Value of a New PharmaceuticalMedical Care, 1998
- Patients’ Preferences for Therapy in Advanced Epithelial Ovarian Cancer: Development, Testing, and Application of a Bedside Decision InstrumentGynecologic Oncology, 1996
- Cost Effectiveness of Tissue Plasminogen ActivatorNew England Journal of Medicine, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemiaAmerican Journal of Hematology, 1995
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsPublished by Elsevier ,1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Clinical decision making: from theory to practice. Anatomy of a decisionPublished by American Medical Association (AMA) ,1990
- Prospect Theory: An Analysis of Decision under RiskEconometrica, 1979
- Judgment under Uncertainty: Heuristics and BiasesScience, 1974